Gritstone bio (GRTS) Stock Price, News & Analysis

Company Overview

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.03 to $0.63
• 52-Week Range: N/A
• Volume: 61.02 million shs
• Average Volume: 7.01 million shs
• Market Capitalization: $3.50 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.17
• Consensus Rating: Moderate Buy

GRTS Stock Analysis - Frequently Asked Questions

How were Gritstone bio's earnings last quarter?

Gritstone bio, Inc. (NASDAQ:GRTS) announced its quarterly earnings data on Tuesday, August, 13th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.12. The business had revenue of $0.92 million for the quarter, compared to analysts' expectations of $2.77 million. Gritstone bio had a negative trailing twelve-month return on equity of 328.51% and a negative net margin of 910.50%.

When did Gritstone bio IPO?

Gritstone bio (GRTS) raised $85 million in an IPO on Friday, September 28th 2018. The company issued 6,100,000 shares at $13.00-$15.00 per share. Goldman Sachs, Cowen and Barclays served as the underwriters for the IPO and BTIG was co-manager.

What other stocks do shareholders of Gritstone bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Gritstone bio investors own include Waste Connections (WCN), AU Optronics (AUOTY), DiamondRock Hospitality (DRH), The RMR Group (RMR), Voyager Therapeutics (VYGR), American Water Works (AWK) and iShares Micro-Cap ETF (IWC).

Company Calendar

• Last Earnings: 8/13/2024
• Today: 7/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GRTS
• CIK: 1656634
• Web: www.gritstoneoncology.com
• Phone: (510) 871-6100
• Fax: N/A
• Employees: 190
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $2.17
• High Stock Price Target: $5.00
• Low Stock Price Target: $0.50
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.24)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$138.49 million
• Net Margins: -910.50%
• Pretax Margin: -910.50%
• Return on Equity: -328.51%
• Return on Assets: -82.53%

Debt

• Debt-to-Equity Ratio: 1.83
• Current Ratio: 2.54
• Quick Ratio: 2.54

Sales & Book Value

• Annual Sales: $496 thousand
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.54 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 108,569,000
• Free Float: 111,837,000
• Market Cap: $3.50 million
• Optionable: Optionable
• Beta: 0.49